dacarbazine has been researched along with Uveitis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amaravadi, RK; Caro, I; Choe, CH; Kempen, JH; McArthur, GA | 1 |
| Chao, D; de Boer, CJ; Gonzalez, R; Gore, ME; Gutzmer, R; Hait, W; Ho, P; Lang, Z; Lawson, D; Loquai, C; Marshall, D; Mohr, P; O'Day, S; Ottensmeier, C; Pavlick, A; Richards, J; Schadendorf, D; Thompson, JA; Trefzer, U; Uhlar, C; Zhong, B | 1 |
2 trial(s) available for dacarbazine and Uveitis
| Article | Year |
|---|---|
Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Conjunctivitis; Dacarbazine; Dry Eye Syndromes; Eye Diseases; Female; Humans; Indoles; Male; Melanoma; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Retrospective Studies; Skin Neoplasms; Sulfonamides; Uveitis; Vemurafenib; Young Adult | 2014 |
A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Female; Humans; Integrin alphaV; Male; Melanoma; Middle Aged; Skin Neoplasms; Uveitis | 2011 |